由青藤属植物、乌头、芍药等植物提取物组成的制剂治疗关节炎及疼痛

US2006110468-A1本品由青藤属(Sinomenium spp.)植物、乌头Aconitum carmichaeli Debx.、芍药Paeonia lactiflora Pall.、牡丹Paeonia suffruticosa Andr.和姜黄Curcuma longa L.提取物组成。将上述植物粉碎后,用溶剂提取至少1次,提取液浓缩、合并即得。本品可治疗关节炎及相关的炎症(如类风湿性关节炎和强直性脊柱炎),缓解疼痛,也可作为营养物。由青藤属植物、乌头、芍药等植物提取物组成的制剂治疗关节炎及疼痛@高展…     

中国介入心脏病学大会(CIT)会议纪要

由中华医学会心血管病学分会、中国介入心脏病学大会(CIT)理事会、美国心血管研究基金会(Cardiovascular ResearchFoundation)-经导管心血管治疗学大会(TCT)、欧洲经皮血管重建治疗大会(EuroPCR)联合主办、中国工程院医药卫生学部等多个单位协办的“中国介入心脏病学大会(CIT)2007暨TCT atCIT和EuroPCR at CIT”于2007年3月29～4月1日在北京国际会议中心召开。来自39个国家和地区的100余位世界知名专家应邀出席大会,近400名来自境外的医生及2500余名国内医生注册参加大会。美国TCT以及欧洲UuroPCR这两个世界最著名的心血管介…     

用参三七、杜仲和黄精组成的草药合剂阻止金属诱导的肝细胞氧化损伤或抑制肝癌发生

US2006105061-A1该草药合剂是以参三七、杜仲和黄精根茎为主要成分,能有效抑制金属(如铜、钒、铁)诱导的肝细胞氧化损害(如脂质过氧化和溶酶体变形),还可抑制肝癌的发生,提高致癌物代谢酶(谷胱甘肽过氧化物酶、谷胱甘肽还原酶、葡萄糖-6-磷酸脱氢酶、过氧化氢酶、谷胱甘肽S-转移酶或醌还原酶)的活性,致癌物代谢酶是细胞色素P450(CYP)异构相酶和相酶。该草药合剂中各成分间具有协同作用,易吸收,起效快,作用持久。用参三七、杜仲和黄精组成的草药合剂阻止金属诱导的肝细胞氧化损伤或抑制肝癌发生@高展…     

用固相微萃取和气-质联用技术分析菘蓝叶中的挥发性成分

异硫腈酸盐是芥属蔬菜中典型的成分,具有化学防癌作用。由于菘蓝Isatis tinctoria L.叶中可能存在挥发性异硫腈酸盐,且对该植物中挥发性成分的研究鲜有报道,因此作者采用顶空固相微萃取(HS-SPME)和气-质(GC-MS)联用技术分析菘蓝叶中的挥发性成分。将3.5g样品溶于含5mL水的管形瓶中,平衡30min,在750r/min条件下搅拌萃取25min,萃取温度30℃。用于分析物热解吸的固定相纤维保持在260℃,共3min,观察多项参数对萃取最佳化的影响。在GC-MS分析中,采用带有Varian2000离子阱质谱仪的Varian3800气相色谱仪。使用2种不同的溶凝硅石毛细管柱:1)…     

医源性食管穿孔15例原因及处理

医源性食管穿孔是一严重疾患，如不及时诊断和治疗，可危及病人生命，死亡率在20％以上。我院1990～2007年共收治医源性食管穿孔15例，效果满意现报道如下。     

含乌司他丁肺保护液在心肺转流术中的肺保护作用

Objective To evaluate protective effects of hypothermic pulmonary protective solution with uli-nastatin on lung function during cardiopulmouary bypass (CPB) in the patients with congenital heart disease(CHD) and pulmonary hypertenion. Method Fifty-four children,who had CHD of left-to-fight shunts with moderate-se-rious pulmonary hypertension, were enrolled. They had been performed with the radical operation under CPB from September 2005 to December 2006 in the Department of Cardiovascular Surgery, Children' s Hospital of Zhejiang University. Moderate-serious pulmonary hypertension was defined as pulmonary-to-systolic pressure ratio > 0.45(Pp/Ps > 0.45). Fifty-four children were randomly divided into three groups. Patients in group A (n = 18)didn't receive pulmonary protective solution, and scrved as control; patients in group B (n = 18) were adminis-tered with pulmonary protective solution without ulinastatin;patients in group C (n = 18) were administered with pulmonary protective solution with ulinastatin. The serum concentrations of MDA and MPO were measured at five different time points:pre-operation, 0 h, 3 h, 6 h and 24 h in the intensive care unit (ICU) (T1～5). Patients'lung functions were monitored at T1 - T4. The time of mechanical ventilation was recorded. Results No one died in this study. The mean time of mechanical ventilation was shorter in the group B and group C than that in the group A. The MDA and MPO levels were lower in group B compared with group A at T4. The MDA level at T3-T5 and the MPO level at T4 was lower in group C than those in group A. There were no significant in MDA and MPO levels between group B and group C at five time point.A-aDO2 was lower in groups B and C than those in group A at T3 and T4, whereas at T4, A-aDO2 was lower in group C than that in group B. Cdyn was higher in group B at T3and group C at T3 - T4 than those in group A. Cdyn was lower in groups C than that in group B at T4.Condusions Lung perfusion with hypothermic protective solution during CPB can all lung injury and promote recovery after operation, especialy with ulinastatin.     

含乌司他丁肺保护液在心肺转流术中的肺保护作用

Objective To evaluate protective effects of hypothermic pulmonary protective solution with uli-nastatin on lung function during cardiopulmouary bypass (CPB) in the patients with congenital heart disease(CHD) and pulmonary hypertenion. Method Fifty-four children,who had CHD of left-to-fight shunts with moderate-se-rious pulmonary hypertension, were enrolled. They had been performed with the radical operation under CPB from September 2005 to December 2006 in the Department of Cardiovascular Surgery, Children' s Hospital of Zhejiang University. Moderate-serious pulmonary hypertension was defined as pulmonary-to-systolic pressure ratio > 0.45(Pp/Ps > 0.45). Fifty-four children were randomly divided into three groups. Patients in group A (n = 18)didn't receive pulmonary protective solution, and scrved as control; patients in group B (n = 18) were adminis-tered with pulmonary protective solution without ulinastatin;patients in group C (n = 18) were administered with pulmonary protective solution with ulinastatin. The serum concentrations of MDA and MPO were measured at five different time points:pre-operation, 0 h, 3 h, 6 h and 24 h in the intensive care unit (ICU) (T1～5). Patients'lung functions were monitored at T1 - T4. The time of mechanical ventilation was recorded. Results No one died in this study. The mean time of mechanical ventilation was shorter in the group B and group C than that in the group A. The MDA and MPO levels were lower in group B compared with group A at T4. The MDA level at T3-T5 and the MPO level at T4 was lower in group C than those in group A. There were no significant in MDA and MPO levels between group B and group C at five time point.A-aDO2 was lower in groups B and C than those in group A at T3 and T4, whereas at T4, A-aDO2 was lower in group C than that in group B. Cdyn was higher in group B at T3and group C at T3 - T4 than those in group A. Cdyn was lower in groups C than that in group B at T4.Condusions Lung perfusion with hypothermic protective solution during CPB can all lung injury and promote recovery after operation, especialy with ulinastatin.     

含乌司他丁肺保护液在心肺转流术中的肺保护作用

Objective To evaluate protective effects of hypothermic pulmonary protective solution with uli-nastatin on lung function during cardiopulmouary bypass (CPB) in the patients with congenital heart disease(CHD) and pulmonary hypertenion. Method Fifty-four children,who had CHD of left-to-fight shunts with moderate-se-rious pulmonary hypertension, were enrolled. They had been performed with the radical operation under CPB from September 2005 to December 2006 in the Department of Cardiovascular Surgery, Children' s Hospital of Zhejiang University. Moderate-serious pulmonary hypertension was defined as pulmonary-to-systolic pressure ratio > 0.45(Pp/Ps > 0.45). Fifty-four children were randomly divided into three groups. Patients in group A (n = 18)didn't receive pulmonary protective solution, and scrved as control; patients in group B (n = 18) were adminis-tered with pulmonary protective solution without ulinastatin;patients in group C (n = 18) were administered with pulmonary protective solution with ulinastatin. The serum concentrations of MDA and MPO were measured at five different time points:pre-operation, 0 h, 3 h, 6 h and 24 h in the intensive care unit (ICU) (T1～5). Patients'lung functions were monitored at T1 - T4. The time of mechanical ventilation was recorded. Results No one died in this study. The mean time of mechanical ventilation was shorter in the group B and group C than that in the group A. The MDA and MPO levels were lower in group B compared with group A at T4. The MDA level at T3-T5 and the MPO level at T4 was lower in group C than those in group A. There were no significant in MDA and MPO levels between group B and group C at five time point.A-aDO2 was lower in groups B and C than those in group A at T3 and T4, whereas at T4, A-aDO2 was lower in group C than that in group B. Cdyn was higher in group B at T3and group C at T3 - T4 than those in group A. Cdyn was lower in groups C than that in group B at T4.Condusions Lung perfusion with hypothermic protective solution during CPB can all lung injury and promote recovery after operation, especialy with ulinastatin.     

生物可降解与非可降解雷帕霉素药物洗脱支架一年临床及七个月造影随访

目的 比较牛物可降解雷帕霉素洗脱支架(Excel,山东古威医疗制品有限公司)和非可降解雷帕霉素洗脱支架(Cypher,美国Cordis公司)的临床效果.方法 回顾性分析从2006年5月至2006年11月在阜外心血管病医院连续置入Excel支架[E组:n:350,(58.1±10.9)岁]和Cypher 支架[C组:n=241,(56.4±10.7)岁]的591例患者.结果 临床基线上E组既往心肌梗死(MI)比率大于C组,左主干病变比率少于C组,而3支病变比率大于C组.基线病变特点上E组参照血管直径、支架卣径、后扩张比率和支架内最小直径均小于C组.两组介入成功率均为100%.主要不良心血管事件发生率E组与C组比较差异无统计学意义(8.3%比7.1%,P=0.641),其巾心原性死亡、非致死性MI和靶血管血运重建率两组差异尤统计学意义(分别为0.9%比0.0%,P=0.274;2.0%比1.2%,P=0.747;5.4%比5.8%,P=0.857).支架内血栓形成发生率E组和C组差异无统计学意义(0.9%比0.4%,P=0.649),早期、晚期支架内血栓形成发牛率两组差异亦无统计学意义(分别为0.6%比0.0%,P=0.516;0.3%比0.4%,P=1.000).7个月造影随访支架内和血管段冉狭窄率E组和C组差异无统计学意义(分别为4.7%比3.2%,P=0.725;5.6%比3.2%,P=0.505),但支架内和血管段的管腔晚期丢失E组均明显小于C组[分别为(0.18 ±0.07)mm比(0.21±0.08)mm,P<0.001;(0.21±0.09)mm比(0.23±0.11)mm,P:0.003].结论 Excel和Cypher支架在真实世界应用具有相似的良好效果.     

左右冠状动脉肺动脉瘘一例

患者女性,39岁,主因"发现心脏杂音38年,发作性胸闷、胸痛3年,加重1个月"收入院.患者38年前查体时发现心脏杂音,诊断为"心脏病",未予诊治.